Our mission
Dedicated to pioneering universal solutions for critical infectious diseases such as HCV, HIV, Influenza A, and JC virus.
R&D Activity
Harnessing the power of human monoclonal antibody cloning as the cornerstone for pioneering vaccine breakthroughs.
Commercial Activity
Empowering businesses with tailored recombinant proteins and customized antibodies to fuel innovation and growth.
Who we are
We are a private Italian
R&D biotech company
Every breakthrough at Pomona Ricerca is driven by our commitment to improving patient outcomes. We strive to enhance the quality of life for individuals by delivering effective and safe immunotherapeutic solutions. At the heart of Pomona Ricerca's vision lies a fervent dedication to advancing research in monoclonal antibodies to prevention and treatment of infectious diseases.
POMONA RICERCA
Our strategy
Pomona Ricerca provides indispensable services in the critical pre-clinical characterization stage of drug development.
The business model of Pomona Ricerca operates on three fronts:
- designing and developing new monoclonal antibodies, followed by out-licensing the mAbs at the pre-clinical characterization stage
- developing of antibody-based vaccines
- providing proteins and services for the characterization of new monoclonal antibodies
Our comprehensive approach, blending consolidated scientific expertise with cutting-edge technologies, positions us as an attractive partner for biotech firms, pharmaceutical companies, and research institutions aiming to bring novel therapeutics to market.
Pomona ricerca
Products & Services
Proteins distribution
Marketing of premium viral proteins of exceptional quality to advance your scientific research.
Custom antibody
Generating, characterizing and engineering monoclonal antibodies sourced from different species.
Custom protein
Customizing your protein design to fit the exact characteristics you require.
Pomona ricerca
News
Seasonal flu vaccines: the importance of being conscious
Interim estimates of this year’s influenza vaccine effectiveness (VE) from Southern Hemisphere countries revea
Mpox Crisis in Africa: The Emergence of Clade 1b and the Race for Effective Vaccination
In a recent news article for Nature, Sara Reardon discussed the spread of Monkeypox in Africa and examined how v
Enhancing anti-HIV vaccine development: the immunogenic potential of the Minibody format
Advancements in medical research have not yet yielded an effective vaccine against different pathogens, with HIV
Pomona ricerca
Partnership
